Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|February 25, 2015
FDA's Compounding Advisory Committee's Effects for Compounding Pharmacists
Lisa Faast, PharmD, pharmacy business specialist and member of Pharmacy Development Services, talks about how the FDA's Compounding Advisory Committee will affect the daily practice of compounding pharmacists.
Advertisement
Lisa Faast, PharmD, pharmacy business specialist and member of Pharmacy Development Services, talks about how the FDA’s Compounding Advisory Committee will affect the daily practice of compounding pharmacists.
This interview was recorded at the Pharmacy Development Services 2015 conference in Orlando, Florida.
Advertisement
Related to this article
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, while sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions of care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.
Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
3
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
4
Not So Rare After All: Pharmacists Weigh In on Diagnosing and Managing ATTR-CM
5